HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NGOs To J&J: End Johnson’s Baby Powder Globally, Or Is Your Black Lives Support A PR Stunt?

Executive Summary

J&J’s targeted marketing of talcum powder products to women of color verges on “corporate brutality,” Black Women for Wellness and more than 200 allied organizations suggest in recent letters to J&J leadership. The firm affirmed its commitment to equality and racial justice in June, but BWW wants J&J to “walk the talk.”

You may also be interested in...



Proposal For J&J To Halt Talc Powder Sales Worldwide Fails In Shareholder Vote

Activist investment group Tulipshare’s proposal that J&J fully cease sales of talc-based powders didn’t receive a majority of votes in favor during firm's annual meeting and won’t be forwarded for board’s consideration. Separate proposal for an audit into whether firm marketed products to minority women asbestos concerns was sent to the board.

J&J’s $4.69Bn Damages From Missouri Trial On Talc-Cancer Link Cut In Half, But Verdict Upheld

J&J’s appeal of largest verdict yet in complaints challenging safety of talc in its Johnson’s Baby Powder and Shower to Shower Shimmer products failed, but a Missouri court cut its damages by more than half. Missouri appellate panel says the firm should pay $500m compensatory and $1.62bn punitive damages.

J&J’s Discontinuation Of Johnson’s Baby Powder Linked To April Federal Court Ruling

Legal experts note that J&J’s decision to end Johnson’s Baby Powder sales in the US and Canada closely followed a New Jersey federal court decision that largely denied the firm’s motions to bar testimony from plaintiff experts in multi-district talc litigation comprising around 16,000 cases.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS150436

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel